American Friends of Rambam Medical Center

American Friends of Rambam Medical Center American Friends of Rambam is a national not-for-profit organization established to promote and support The Rambam Health Care Campus in Haifa, Israel

Calling all New York-area friends and supporters of American Friends of Rambam:Join us for an intimate evening with Prof...
06/11/2026

Calling all New York-area friends and supporters of American Friends of Rambam:

Join us for an intimate evening with Professor Rafael Beyar, former Director General of Rambam Health Care Campus, for a timely conversation about Rambam’s lifesaving work during the war in northern Israel, groundbreaking medical innovation, and the future of the Neurosciences Institute.

Wednesday, June 24 at 6:30 PM
Upper West Side, Manhattan
Address provided upon RSVP

Space is limited. RSVP by June 19.

Severely Injured by Drone in Lebanon, Israeli Reservist Plans Return to His UnitJune 11, 2026 — Although no longer requi...
06/11/2026

Severely Injured by Drone in Lebanon, Israeli Reservist Plans Return to His Unit

June 11, 2026 — Although no longer required to serve, 50-year-old Sergey Beskorovainy continued answering the call to reserve duty. Severely wounded by a drone near Israel’s northern border, he is now undergoing treatment at Rambam Health Care Campus in Haifa—and already planning his return to his unit.

Master Sergeant (res.) Sergey Beskorovainy, 50, from Migdal HaEmek in Northern Israel, was severely injured in Southern Lebanon after a drone strike. He was evacuated to Rambam Health Care Campus (Rambam) in Haifa, where he underwent two complex head surgeries and received treatment for shrapnel wounds throughout his body, as well as injuries to his arm and left leg.

Read more here: https://www.facebook.com/share/p/18dGyoZ74F/?mibextid=wwXIfr

Severely Injured by Drone in Lebanon, Israeli Reservist Plans Return to His UnitAlthough no longer required to serve, 50...
06/11/2026

Severely Injured by Drone in Lebanon, Israeli Reservist Plans Return to His Unit

Although no longer required to serve, 50-year-old Sergey Beskorovainy continued answering the call to reserve duty. Severely wounded by a drone near Israel’s northern border, he is now undergoing treatment at Rambam Health Care Campus in Haifa—and already planning his return to his unit.

Master Sergeant (res.) Sergey Beskorovainy, 50, from Migdal HaEmek in Northern Israel, was severely injured in Southern Lebanon after a drone strike. He was evacuated to Rambam Health Care Campus (Rambam) in Haifa, where he underwent two complex head surgeries and received treatment for shrapnel wounds throughout his body, as well as injuries to his arm and left leg.

His wife, Yana, has been by his side for the past month at Rambam and shares the details of the attack. The drone had descended rapidly toward the soldiers, leaving little time to react or find adequate cover. She explains that soldiers have almost no chance of escaping once a drone locks onto its target; yet Sergey is already making plans to return to his unit.

Beskorovainy wanted to be sure everyone understood that the operational environment in Lebanon differs significantly from that in Gaza. From his hospital bed, he quietly asks his wife to explain: “Lebanon is not Gaza.”

The family lives in Migdal HaEmek with their two daughters, Anastasia, eighteen, and Sofia, four and a half. Although exempt from reserve duty because of his age, Beskorovainy has continued to volunteer whenever called. Since the October 7 attacks, Yana says, he has remained on active reserve service despite her repeated pleas that he had already given enough after decades of service.

Despite his extensive prior combat experience, including two and a half years of service in Gaza under numerous challenging conditions, Beskorovainy attempted to escape and take cover, but the drone struck the group, severely injuring him and wounding two additional soldiers, one moderately and one lightly. Having since undergone two head surgeries, he remains in good spirits and maintains a positive outlook on recovery.

After completing treatment at Rambam, he faces a long road of rehabilitation. Despite the severity of his injuries, he remains committed to his unit and has expressed a strong desire to rejoin his fellow soldiers as soon as possible.

Based on an original Hebrew language article that first appeared on ynet.

First in Northern Israel: Innovative Knee Cartilage Repair Using a Coral-Based ImplantRambam Health Care Campus (Rambam)...
06/09/2026

First in Northern Israel: Innovative Knee Cartilage Repair Using a Coral-Based Implant

Rambam Health Care Campus (Rambam) is offering a new surgical option for patients with localized cartilage and bone injuries in the knee: a coral-based biological implant designed to support bone and cartilage regeneration.

The Knee and Arthroscopy Unit, part of Rambam’s Orthopedic Surgery Section, brings new hope to residents of Northern Israel with knee damage.

Until now, patients with localized knee cartilage and bone injuries that did not require knee replacement were often treated with an autologous graft—tissue taken from another part of the patient’s own knee and transplanted into the damaged area. The new procedure involves placement of a coral-based biological implant that supports the growth of new bone and cartilage tissue, helping repair damage in the knee joint. The new procedure offers potentially better patient outcomes, including less pain, fewer complications, and faster rehabilitation.

A series of these surgeries was recently performed at Rambam for the first time in Northern Israel. The procedures were done by senior physicians from Rambam’s Knee and Arthroscopy Unit team, and sports medicine unit, in the Orthopedic Surgery Section, led by Dr. Bezalel Peskin, together with attending physicians Dr. Mazen Falah, Dr. Barak Segal, Dr. Shadi Sadia, Dr. Shahem Elias, and Dr. Pavel Kotlyarsky.

A Targeted Option for Young People and Athletes
The implant was developed by the Israeli startup CartiHeal and is marketed by the international company Smith+Nephew. It is made from a laboratory-processed coral scaffold. Because the implant is porous, it acts as a framework that allows natural bone and cartilage cells to grow into it. Over time, the implant is absorbed by the body while supporting the growth of new bone and cartilage tissue. The treatment has received U.S. Food and Drug Administration (FDA) approval.

Implantation of the coral-based scaffold eliminates the need for complex autologous grafting and offers significant advantages, including the potential for less pain and fewer complications, as no bone needs to be taken from another part of the knee, meaning healthy areas remain unaffected by the graft-harvesting process. In addition, the coral-based implant is available for off-the-shelf immediate use, making it particularly applicable in cases where the patient does not have suitable tissue for grafting. Furthermore, by avoiding traditional autologous grafting, this approach may support a faster and less complex rehabilitation process compared with previous methods.

According to Rambam physicians, this new surgical option may improve quality of life for young patients and athletes in Northern Israel by expanding the treatment options available for focal cartilage and bone injuries in the knee.

Following the Iranian missile attacks yesterday, and under the direction of the Ministry of Health and the Home Front Co...
06/08/2026

Following the Iranian missile attacks yesterday, and under the direction of the Ministry of Health and the Home Front Command, starting this morning, thousands of hospital staff have mobilized and are working intensively to prepare the hospital and its infrastructure for full operations. Patients are already being transferred from our unfortified aboveground facilities to the Fortified Underground Emergency Hospital.

As Northern Israel's committed security asset, we're always present, alert, and ready to respond.

Join our mission and donate today! www.aforam.org/donate

Breakthrough in Pancreatic Cancer Biopsy TechnologyInspired by the act of coring zucchinis and a pressing clinical need,...
06/04/2026

Breakthrough in Pancreatic Cancer Biopsy Technology

Inspired by the act of coring zucchinis and a pressing clinical need, a Rambam physician helped develop a new medical device that improves tissue sampling for pancreatic cancer diagnosis and is now being used by medical centers in the United States.

Professor Iyad Khamaysi, director of the Advanced Endoscopy Unit at Rambam, and a leading authority in ultrasound-guided biopsy procedures, had long encountered the limitations of conventional diagnostic tools for pancreatic tumors. These procedures were often time-consuming, required repeat interventions, and frequently produced fragmented or blood-contaminated samples that were insufficient for accurate pathological evaluation. In up to 20% of cases, patients required a second biopsy under sedation due to inadequate tissue quality.

Khamaysi conceptualized a new approach inspired by an everyday occurrence: coring zucchinis to prepare them for stuffing. Further developing that idea at Rambam, he envisioned a biopsy device capable of extracting intact core tissue from a targeted organ through precisely controlled rotation, potentially improving sample quality, diagnostic reliability, and clinical outcomes. This idea laid the foundation for a collaboration with the Trendlines Group, which had approached Rambam to identify unmet clinical needs. The partnership led to establishing Limaca Medical in 2017.

Read more here: https://www.facebook.com/share/p/1EeUxHiWvv/

Breakthrough in Pancreatic Cancer Biopsy TechnologyInspired by the act of coring zucchinis and a pressing clinical need,...
06/04/2026

Breakthrough in Pancreatic Cancer Biopsy Technology

Inspired by the act of coring zucchinis and a pressing clinical need, a Rambam physician helped develop a new medical device that improves tissue sampling for pancreatic cancer diagnosis and is now being used by medical centers in the United States.

Professor Iyad Khamaysi, director of the Advanced Endoscopy Unit at Rambam, and a leading authority in ultrasound-guided biopsy procedures, had long encountered the limitations of conventional diagnostic tools for pancreatic tumors. These procedures were often time-consuming, required repeat interventions, and frequently produced fragmented or blood-contaminated samples that were insufficient for accurate pathological evaluation. In up to 20% of cases, patients required a second biopsy under sedation due to inadequate tissue quality.

Khamaysi conceptualized a new approach inspired by an everyday occurrence: coring zucchinis to prepare them for stuffing. Further developing that idea at Rambam, he envisioned a biopsy device capable of extracting intact core tissue from a targeted organ through precisely controlled rotation, potentially improving sample quality, diagnostic reliability, and clinical outcomes. This idea laid the foundation for a collaboration with the Trendlines Group, which had approached Rambam to identify unmet clinical needs. The partnership led to establishing Limaca Medical in 2017.

The resulting FDA-approved Precision-GI™ system represents a motorized, next-generation alternative to conventional biopsy tools. By enabling rotational tissue acquisition, the device produces high-quality core samples suitable for advanced diagnostic techniques, including molecular profiling. Unlike traditional manual devices, it reduces dependence on operator variability and improves procedural consistency. Clinical studies showed improved procedural efficiency and superior histological quality compared to standard fine-needle biopsy methods. These improvements are particularly significant in pancreatic cancer, where timely and accurate diagnosis is critical for treatment planning and patient outcomes.

The technology has since been introduced into leading medical centers in the U.S., with more than 300 procedures performed to date. Physicians reported strong clinical and operational benefits.



Building on its clinical and commercial momentum, Limaca Medical is now expanding globally, with Japan identified as the next key market. Registration efforts are underway, with commercialization expected to follow.

Less than a decade after its inception, the initiative led by Khamaysi has evolved into a rapidly growing medical technology success. The Precision-GI™ platform underscores Rambam’s role as a center for physician-driven innovation and highlights the impact of translating clinical insight into solutions that improve diagnostic accuracy and patient care worldwide.

Adapted from an original English-language article that first appeared on Haaretz.com.

06/04/2026
A High-Risk Pregnancy, a Rare Disease, and a Baby Saved at RambamMay 31, 2026 – When Gal Tayib’s high-risk pregnancy bec...
06/01/2026

A High-Risk Pregnancy, a Rare Disease, and a Baby Saved at Rambam

May 31, 2026 – When Gal Tayib’s high-risk pregnancy became a medical emergency at 33 weeks, specialists at Rambam Health Care Campus (Rambam) moved quickly to save two lives: hers and her baby’s.

In 2020, physicians diagnosed Netanya resident Gal Tayib (29) with myasthenia gravis, a chronic, potentially life-threatening autoimmune disease that disrupts communication between nerves and muscles. For years, the disease remained dormant until she became pregnant. The pregnancy triggered a flare-up and tragically ended in miscarriage.

Thereafter, Tayib began a first-of-its-kind biological therapy in Israel under the supervision of Dr. Shahar Shelly, director of the Department of Neurology at Rambam. Once her condition stabilized, and while under close medical supervision, she conceived again.

Read more here: https://www.facebook.com/share/p/18zKkY1UQN/

A High-Risk Pregnancy, a Rare Disease, and a Baby Saved at RambamWhen Gal Tayib’s high-risk pregnancy became a medical e...
06/01/2026

A High-Risk Pregnancy, a Rare Disease, and a Baby Saved at Rambam

When Gal Tayib’s high-risk pregnancy became a medical emergency at 33 weeks, specialists at Rambam Health Care Campus (Rambam) moved quickly to save two lives: hers and her baby’s.

In 2020, physicians diagnosed Netanya resident Gal Tayib (29) with myasthenia gravis, a chronic, potentially life-threatening autoimmune disease that disrupts communication between nerves and muscles. For years, the disease remained dormant until she became pregnant. The pregnancy triggered a flare-up and tragically ended in miscarriage.

Thereafter, Tayib began a first-of-its-kind biological therapy in Israel under the supervision of Dr. Shahar Shelly, director of the Department of Neurology at Rambam. Once her condition stabilized, and while under close medical supervision, she conceived again.

The pregnancy progressed well, but during the final trimester—against a backdrop of security tensions and growing anxiety—Tayib faced another battle. Her myasthenia symptoms worsened, including drooping eyelids and severe muscle weakness. Despite increased medication dosages and the addition of steroid treatment, her condition continued to deteriorate. Tests performed at the hospital then revealed severe preeclampsia, creating an immediate danger to both Tayib and the fetus.

Dr. Yaniv Zipori, director of Obstetrics B at Rambam, explains that the treatments for the two conditions conflicted with one another. “Because of her underlying condition, our options were limited,” says Dr. Zipori. “We had no choice but to proceed toward delivery with one clear goal—to keep both mother and baby alive. In effect, the delivery itself became the treatment.”

At 33 weeks’ gestation, physicians performed an emergency Caesarean section. Simultaneously, Tayib’s medical team replaced her biologic therapy with rapid antibody-reduction treatment and plasma exchange, a process demanding extraordinary coordination among Rambam’s blood bank, operating rooms, neonatal intensive care unit, and Division of Obstetrics and Gynecology.

“Rambam operated as one beating heart,” says Dr. Shelly. “Both her life and the baby’s life were in danger.”

The baby was born with myasthenia symptoms and required ventilation and specialized drug therapy. The medication is not routinely supplied, and had been difficult to obtain since 2021, but determined efforts succeeded in locating and transferring it to the Neonatal Intensive Care Unit.

According to Tayib, he recovered quickly and improved from day to day. After approximately one month of hospitalization, he was discharged home.

After the birth, Tayib also faced breathing difficulties and severe muscle weakness, requiring plasma exchange treatment in Rambam’s Department of Neurology. Despite the ordeal, she remains determined. “It was extremely difficult,” she says, “but I still want more children. I received a gift worth everything.”

Based on an original Hebrew article that first appeared on Mako.

Address

2248 Broadway #2021
New York, NY
10024

Alerts

Be the first to know and let us send you an email when American Friends of Rambam Medical Center posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to American Friends of Rambam Medical Center:

Share